AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32410519 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction and local steroid injection (Group B)
Number of subjects: 84
Study 32410519 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (Group C)
Number of subjects: 84
Study 32212778 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of displacement after the disaster
Number of subjects: 345
Study 32212778 — intervention group
Group type: COMPARATOR
Intervention: Control for age, gender, and traumatic exposure severity
Number of subjects: 345
Study 35190345 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium prevention group (n = 284)
Number of subjects: 609
Study 35190345 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (n = 274)
Number of subjects: 609
Study 33216167 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (7 mg/24 h, transdermally)
Number of subjects: 18
Study 33216167 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine (7.5 mg, p.o.)
Number of subjects: 18
Study 33216167 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 18
Study 32473556 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional training with blood flow restriction (FTBFR)
Number of subjects: 30
Study 32473556 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional training (FT)
Number of subjects: 30
Study 32473556 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study 34902004 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - fluticasone propionate, 50 μg, with placebo, 2 puffs twice daily for 12 weeks
Number of subjects: 53
Study 34902004 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids and long-acting β2 agonists (ICS/LABA) - fluticasone propionate, 50 μg, with salmeterol, 25 μg, 2 puffs twice daily for 12 weeks
Number of subjects: 53
Study 34902004 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalers
Number of subjects: 53
Study 35524890 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention (8 sessions over 4 weeks)
Number of subjects: 267
Study 35524890 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Didactic health promotion group)
Number of subjects: 267
Study 35524890 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention
Number of subjects: 267
Study 32361959 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater weight bath traction therapy and NSAIDs
Number of subjects: 176
Study 32361959 — intervention group
Group type: COMPARATOR
Intervention: Weight bath
Number of subjects: 176
Study 32361959 — intervention group
Group type: COMPARATOR
Intervention: Only NSAIDs
Number of subjects: 176
Study 36191725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 2900
Study 36191725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2900
Study 33638928 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Er: YAG laser and autologous platelet-rich plasma (PRP)
Number of subjects: 32
Study 33638928 — intervention group
Group type: COMPARATOR
Intervention: Er: YAG laser
Number of subjects: 32
Study 32847985 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab retreatment
Number of subjects: 70
Study 35643769 — intervention group
Group type: EXPERIMENTAL
Intervention: HM3+VP
Number of subjects: 2200
Study 33297866 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase at 0.6 mg/kg intravenously
Number of subjects: 126
Study 33297866 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 126
Study 32317109 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release therapy (5 sessions over 2 weeks)
Number of subjects: 54
Study 32317109 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy program (10 sessions of massage, ultrasound therapy, and transcutaneous electric nerve stimulation over 2 weeks)
Number of subjects: 54
Study 32317109 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release therapy
Number of subjects: 54
Study 36056444 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR-CMR protocol
Number of subjects: 250
Study 36056444 — intervention group
Group type: COMPARATOR
Intervention: TAVR-CT protocol
Number of subjects: 250
Study 35414801 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet + hospital-to-home (H2H) model
Number of subjects: 120
Study 35414801 — intervention group
Group type: COMPARATOR
Intervention: Normal nutritional nursing model (Control)
Number of subjects: 120
Study 33974559 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 223
Study 33974559 — intervention group
Group type: COMPARATOR
Intervention: Normal control plasma
Number of subjects: 223
Study 32321955 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assembling peptide P11-4 (SAP)
Number of subjects: 23
Study 32321955 — intervention group
Group type: COMPARATOR
Intervention: Control teeth (no treatment)
Number of subjects: 23
Study 35098880 — intervention group
Group type: EXPERIMENTAL
Intervention: Matching methods using real-world data (RWD) as control arm
Number of subjects: 0
Study 35098880 — intervention group
Group type: COMPARATOR
Intervention: Historical control data
Number of subjects: 0
Study 33592197 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management strategies (healthcare use, lifestyle changes, positive coping, avoidance)
Number of subjects: 267
Study 36209050 — intervention group
Group type: EXPERIMENTAL
Intervention: Early child stimulation (categorized as low, moderate, and high stimulation based on PROCESS scores)
Number of subjects: 516
Study 36209050 — intervention group
Group type: EXPERIMENTAL
Intervention: Early child stimulation (moderate to high quality)
Number of subjects: 516
Study 34529811 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated gum (4 mg/kg)
Number of subjects: 39
Study 34529811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 36086732 — intervention group
Group type: EXPERIMENTAL
Intervention: Married patients
Number of subjects: 5477
Study 36086732 — intervention group
Group type: EXPERIMENTAL
Intervention: Single/unmarried patients
Number of subjects: 5477
Study 36086732 — intervention group
Group type: EXPERIMENTAL
Intervention: Separated/widowed/divorced patients
Number of subjects: 5477
Study 35255814 — intervention group
Group type: EXPERIMENTAL
Intervention: Near point-of-care CT and NG testing and treatment intervention
Number of subjects: 0
Study 35255814 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care (WHO-endorsed syndromic management)
Number of subjects: 0
Study 34068577 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure with six short photo stories
Number of subjects: 471
Study 34068577 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-narrative brochure with comparable photos
Number of subjects: 471
Study 34068577 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional brochure
Number of subjects: 471
Study 34068577 — intervention group
Group type: COMPARATOR
Intervention: All brochure versions
Number of subjects: 471
Study 32658797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus ropivacaine (1 μg kg−1 dexmedetomidine and 0.25% ropivacaine)
Number of subjects: 120
Study 32658797 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine alone (0.25% ropivacaine)
Number of subjects: 120
Study 32658797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus ropivacaine
Number of subjects: 120
Study 35555278 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB+D (3g of HMB + 2000IU of Vitamin D3)
Number of subjects: 43
Study 35555278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 33148538 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37756542 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine U-100
Number of subjects: 5047
Study 37756542 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 5047
Study 33451627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (1000 mg)
Number of subjects: 121
Study 33451627 — intervention group
Group type: COMPARATOR
Intervention: Oral acetaminophen (1000 mg)
Number of subjects: 121
Study 34748929 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Closure (LAAC)
Number of subjects: 402
Study 34748929 — intervention group
Group type: COMPARATOR
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 402
Study 32046665 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab monotherapy
Number of subjects: 133
Study 32046665 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront combination therapy
Number of subjects: 133
Study 32046665 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 133
Study 32046665 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring HER2ECD levels
Number of subjects: 133
Study 32046665 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2ECD baseline levels
Number of subjects: 133
Study 35130964 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparing for Sustainment (PS)
Number of subjects: 360
Study 35130964 — intervention group
Group type: COMPARATOR
Intervention: Sustainment as Usual (SAU)
Number of subjects: 360
Study 34142483 — intervention group
Group type: EXPERIMENTAL
Intervention: Drowning cases (31)
Number of subjects: 154
Study 34142483 — intervention group
Group type: COMPARATOR
Intervention: Non-drowning cases (123)
Number of subjects: 154
Study 34863879 — intervention group
Group type: EXPERIMENTAL
Intervention: Zataria multiflora 5 mg/kg/day (Z5)
Number of subjects: 36
Study 34863879 — intervention group
Group type: EXPERIMENTAL
Intervention: Zataria multiflora 10 mg/kg/day (Z10)
Number of subjects: 36
Study 35112475 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids (3 grams per day)
Number of subjects: 40
Study 35112475 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 35112475 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids
Number of subjects: 40
Study 34678860 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 80
Study 34678860 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 35235834 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention with just-in-time adaptive intervention (JITAI) promoting low-level physical activity and exercise, including access to activity tracking and goal setting through a mobile application, and weekly activity summaries via email.
Number of subjects: 0
Study 35235834 — intervention group
Group type: COMPARATOR
Intervention: Usual care with a compatible smartwatch (Fitbit Versa 2 or Apple Watch 4).
Number of subjects: 0
Study 33202916 — intervention group
Group type: EXPERIMENTAL
Intervention: fiber‐focused point‐of‐decision prompt (PDP)
Number of subjects: 753
Study 33202916 — intervention group
Group type: COMPARATOR
Intervention: no‐PDP condition (control)
Number of subjects: 753
Study 33608239 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA PzF stent followed by very short duration (14 days) DAPT
Number of subjects: 996
Study 33608239 — intervention group
Group type: COMPARATOR
Intervention: FDA-approved new generation drug-eluting stent followed by guideline-recommended DAPT duration (3 or 6 months)
Number of subjects: 996
Study 34034268 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (15 mg daily) and albumin (20 g weekly) in group‐A (Gp‐A)
Number of subjects: 42
Study 34034268 — intervention group
Group type: COMPARATOR
Intervention: Albumin (20 g weekly) alone in group‐B (Gp‐B)
Number of subjects: 42
Study 36050743 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted strategy (implementation teams, educational meeting, ongoing training, Plan-Do-Study-Act cycles)
Number of subjects: 55
Study 36050743 — intervention group
Group type: COMPARATOR
Intervention: Single strategy (implementation teams, educational meeting)
Number of subjects: 55
Study 34516489 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral active engagement training
Number of subjects: 148
Study 34516489 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 148
Study 33872448 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral antibiotics with mechanical bowel preparation (MBP)
Number of subjects: 0
Study 33872448 — intervention group
Group type: COMPARATOR
Intervention: Preoperative oral antibiotics without mechanical bowel preparation (control)
Number of subjects: 0
Study 33872448 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral antibiotics with MBP
Number of subjects: 0
Study 33872448 — intervention group
Group type: COMPARATOR
Intervention: Preoperative oral antibiotics without MBP (control)
Number of subjects: 0
Study 33057642 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital plasma administration (2 units of thawed plasma)
Number of subjects: 166
Study 33057642 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital plasma administration
Number of subjects: 166
Study 33057642 — intervention group
Group type: COMPARATOR
Intervention: Standard care resuscitation
Number of subjects: 166
Study 35505620 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual behavioural intervention (3 sessions of 1 hour each)
Number of subjects: 94
Study 35505620 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 94
Study 33352600 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine phytoplankton supplementation
Number of subjects: 0
Study 33352600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33352600 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine phytoplankton 2.55 mg·d‐1
Number of subjects: 0
Study 33352600 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine phytoplankton 5.1 mg·d‐1
Number of subjects: 0
Study 33352600 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study 33352600 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 0
Study 32281081 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity exercise intervention (50 minutes, three times a week for 12 weeks)
Number of subjects: 100
Study 32281081 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 100
Study 34255042 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol levels (high)
Number of subjects: 311675
Study 32697559 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric contact lenses
Number of subjects: 35
Study 32697559 — intervention group
Group type: COMPARATOR
Intervention: Spherical contact lenses
Number of subjects: 35
Study 36282295 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 28008
Study 36282295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28008
Study 34744149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (20 mg)
Number of subjects: 0
Study 34744149 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (20 mg)
Number of subjects: 0
Study 35460392 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 986 (up to 650 mg/day)
Number of subjects: 182
Study 35460392 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 986
Number of subjects: 182
Study 35460392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 33653320 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratiopeptidase
Number of subjects: 133
Study 33653320 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol + Serratiopeptidase
Number of subjects: 133
Study 33653320 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Paracetamol
Number of subjects: 133
Study 32106714 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab
Number of subjects: 38
Study 34075419 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (RCTs)
Number of subjects: 133
Study 34075419 — intervention group
Group type: COMPARATOR
Intervention: Various interventions (non-randomized studies)
Number of subjects: 133
Study 32989543 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine injection
Number of subjects: 91
Study 32989543 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 91
Study 36088057 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolutex (25 mg daily)
Number of subjects: 65
Study 36088057 — intervention group
Group type: COMPARATOR
Intervention: Crinone (90 mg daily)
Number of subjects: 65
Study 33874917 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based aftercare (digIRENA)
Number of subjects: 1150
Study 33874917 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional face-to-face aftercare (IRENA)
Number of subjects: 1150
Study 33874917 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1150
Study 35608457 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 42
Study 35608457 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 42
Study 34023219 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 485
Study 32062671 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab combination therapy
Number of subjects: 96
Study 32062671 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab as an alternative treatment
Number of subjects: 96
Study 32062671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab treatment for ≥10 months
Number of subjects: 96
Study 33123978 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide
Number of subjects: 149
Study 33123978 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 149
Study 35569811 — intervention group
Group type: EXPERIMENTAL
Intervention: AirSeal insufflation system with pneumoperitoneum between 8 and 10 mm Hg
Number of subjects: 80
Study 35569811 — intervention group
Group type: COMPARATOR
Intervention: Standard insufflation system with pneumoperitoneum between 12 and 15 mm Hg
Number of subjects: 80
Study 35569811 — intervention group
Group type: EXPERIMENTAL
Intervention: AirSeal insufflation system
Number of subjects: 80
Study 35569811 — intervention group
Group type: COMPARATOR
Intervention: Standard insufflation system
Number of subjects: 80
Study 33990437 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative parasternal plane block (PSB) using ropivacaine
Number of subjects: 35
Study 33990437 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo group)
Number of subjects: 35
Study 33152467 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF MDI 320/18/9.6 μg
Number of subjects: 264
Study 33152467 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF MDI 160/18/9.6 μg
Number of subjects: 264
Study 33152467 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF MDI (both doses)
Number of subjects: 264
Study 33152467 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF MDI
Number of subjects: 264
Study 35871718 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa (NS) oil supplementation (2 g/daily for 8 weeks)
Number of subjects: 60
Study 35871718 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (placebo)
Number of subjects: 60
Study 33341916 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive distal pancreatectomy (MIDP)
Number of subjects: 5
Study 33341916 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive pancreatoduodenectomy (MIPD)
Number of subjects: 5
Study 33341916 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic pancreatoduodenectomy (MIPD)
Number of subjects: 5
Study 32197620 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF6001 800 μg BID
Number of subjects: 54
Study 32197620 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF6001 1600 μg BID
Number of subjects: 54
Study 32197620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 34000754 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic arm-assisted THA
Number of subjects: 99
Study 32561266 — intervention group
Group type: EXPERIMENTAL
Intervention: HTX-011 400 mg bupivacaine/12 mg meloxicam
Number of subjects: 232
Study 32561266 — intervention group
Group type: EXPERIMENTAL
Intervention: HTX-011 400 mg bupivacaine/12 mg meloxicam with 50 mg ropivacaine
Number of subjects: 232
Study 32561266 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine hydrochloride (HCl) 125 mg injection
Number of subjects: 232
Study 32561266 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo injection
Number of subjects: 232
Study 32889881 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Oral Anticoagulant (NOAC) therapy
Number of subjects: 0
Study 32889881 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 32132845 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel eccentric overload group (FEO)
Number of subjects: 34
Study 34309740 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training combined with dual tasks (PFMT‐DT)
Number of subjects: 88
Study 34309740 — intervention group
Group type: COMPARATOR
Intervention: Control group (physical training only)
Number of subjects: 88
Study 33285008 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (15 IU.kg−1 based on factor IX)
Number of subjects: 50
Study 33285008 — intervention group
Group type: COMPARATOR
Intervention: Fresh frozen plasma (15 ml.kg−1)
Number of subjects: 50
Study 33285008 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate
Number of subjects: 50
Study 33285008 — intervention group
Group type: COMPARATOR
Intervention: Fresh frozen plasma
Number of subjects: 50
Study 33285008 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate and fresh frozen plasma
Number of subjects: 50
Study 34500234 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary disease model beliefs with stigmatising language
Number of subjects: 244
Study 34500234 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuum beliefs
Number of subjects: 244
Study 34500234 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 244